Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice
Open Access
- 1 January 2013
- journal article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 6 (6), 1448-1458
- https://doi.org/10.1242/dmm.012849
Abstract
In mice, induced global disruption of the Ptpn11 gene, which encodes the SHP-2 tyrosine phosphatase, results in severe skeletal abnormalities. To understand the extent to which skeletal abnormalities can be attributed to perturbation of SHP-2 function in bone-forming osteoblasts and chondrocytes, we generated mice in which disruption of Ptpn11 is restricted to mesenchymal stem cells (MSCs) and their progeny, which include both cell types. MSC-lineage-specific SHP-2 knockout (MSC SHP-2 KO) mice exhibited postnatal growth retardation, limb and chest deformity, and calvarial defects. These skeletal abnormalities were associated with an absence of mature osteoblasts and massive chondrodysplasia with a vast increase in the number of terminally differentiated hypertrophic chondrocytes in affected bones. Activation of mitogen activated protein kinases (MAPKs) and protein kinase B (PKB; also known as AKT) was impaired in bone-forming cells of MSC SHP-2 KO mice, which provides an explanation for the skeletal defects that developed. These findings reveal a cell-autonomous role for SHP-2 in bone-forming cells in mice in the regulation of skeletal development. The results add to our understanding of the pathophysiology of skeletal abnormalities observed in humans with germline mutations in the PTPN11 gene (e.g. Noonan syndrome and LEOPARD syndrome).Keywords
This publication has 61 references indexed in Scilit:
- LEOPARD Syndrome: Clinical Features and Gene MutationsMolecular Syndromology, 2012
- Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short statureProceedings of the National Academy of Sciences of the United States of America, 2012
- Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromesHuman Molecular Genetics, 2008
- PTPN11 Mutations Are Associated with Mild Growth Hormone Resistance in Individuals with Noonan SyndromeJournal of Clinical Endocrinology & Metabolism, 2005
- SHP-2 Positively Regulates Myogenesis by Coupling to the Rho GTPase Signaling PathwayMolecular and Cellular Biology, 2004
- Grouping of Multiple-Lentigines/LEOPARD and Noonan Syndromes on the PTPN11 GeneAmerican Journal of Human Genetics, 2002
- Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancergenesis, 2002
- Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase AktOncogene, 2000
- Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2Structure, 1998
- Multiple Lentigenes SyndromeAmerican Journal of Diseases of Children, 1969